Welcome to AiCuris
Clear Focus on Anti-Infective Cures
AiCuris (name derived from 'anti-infective cures') is a pharmaceutical company focused exclusively on the discovery, research and development of novel antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases. AiCuris has its roots in Bayer's long history of successful anti-infective drugs. It is built around Bayer's portfolio of antiviral and antibacterial R&D programs, compounds and intellectual property and it is run by experts from Bayer's virology and bacteriology research. CEO of AiCuris is Prof. Dr. Helga Rübsamen-Schaeff, the former Senior Vice President and Head of Anti-Infective Research at Bayer. Majority investors are Drs. Strüngmann, the founders and previous owners of Hexal.
- broad and 100 % innovative pipeline from one of the leading pharmaceutical companies in the field of anti-infectives
- concentration on specialist markets with high medical need
- team of internationally highly recognized scientists with the knowhow of major pharmaceutical companies
- and the support by its majority investors, the Drs. Strüngmann,
AiCuris is primed to prosper and to bring innovative drugs to the market for patients with severe, life-threatening infections.
AiCuris is a member of BioDeutschland
AiCuris was one of the participating companies at the first Innovation Prize of the german economy in 2011